Top Page
Cytosorbents
(NASDAQ:CTSO)
Cytosorbents (CTSO) vs. SPDR S&P 500 ETF (SPY)
Cytosorbents Business Overview & Revenue Model
Cytosorbents Earnings Call Summary
Cytosorbents Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 35.59M | 36.35M | 29.36M | 40.11M | 39.45M |
| Gross Profit | 25.13M | 21.95M | 15.40M | 29.06M | 28.40M |
| EBITDA | -19.26M | -29.18M | -30.00M | -22.01M | -9.71M |
| Net Income | -20.72M | -28.51M | -32.81M | -24.56M | -7.84M |
Balance Sheet | |||||
| Total Assets | 47.37M | 53.26M | 63.23M | 89.52M | 89.95M |
| Cash, Cash Equivalents and Short-Term Investments | 3.28M | 14.13M | 22.14M | 52.14M | 71.42M |
| Total Debt | 26.89M | 18.31M | 18.25M | 13.82M | 1.03M |
| Total Liabilities | 36.26M | 29.99M | 27.86M | 26.94M | 10.73M |
| Stockholders Equity | 11.11M | 23.28M | 35.38M | 62.58M | 79.22M |
Cash Flow | |||||
| Free Cash Flow | -14.71M | -22.59M | -34.69M | -18.29M | -7.29M |
| Operating Cash Flow | -14.43M | -21.66M | -28.23M | -14.01M | -5.61M |
| Investing Cash Flow | -669.43K | -936.24K | -6.46M | -4.28M | -1.68M |
| Financing Cash Flow | 9.33M | 14.47M | 4.96M | 715.20K | 66.35M |
Cytosorbents Technical Analysis
Cytosorbents Risk Analysis
Cytosorbents Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $97.55M | 13.21 | 5.00% | ― | 0.29% | -22.13% | |
66 Neutral | $75.48M | 41.67 | 3.46% | ― | 24.75% | -61.29% | |
57 Neutral | $90.63M | ― | -26.20% | ― | 20.81% | -498.66% | |
52 Neutral | $60.64M | ― | -67.86% | ― | 0.34% | 6.20% | |
52 Neutral | $7.53B | 0.20 | -61.87% | 2.28% | 16.72% | 1.10% | |
50 Neutral | $74.44M | ― | -113.95% | ― | 8.49% | 6.09% | |
49 Neutral | $69.50M | ― | -94.65% | ― | -5.86% | 50.76% |
Cytosorbents Corporate Events
On July 2, 2025, CytoSorbents Corporation announced regulatory updates regarding its DrugSorb-ATR device. The U.S. FDA scheduled an appeal hearing for the company’s supervisory review, while Health Canada issued a Notice of Refusal for the Medical Device License application due to non-compliance issues. CytoSorbents plans to address these concerns through the appeals process, aiming for final regulatory decisions by the end of 2025. The company believes DrugSorb-ATR offers a unique solution for reducing perioperative bleeding in cardiac surgery, addressing a critical need in the U.S. and Canadian markets.
The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
On June 24, 2025, CytoSorbents Corporation announced its decision to appeal the U.S. FDA’s denial of its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding severity in patients undergoing coronary artery bypass grafting. The company filed for a supervisory review on June 18, 2025, aiming to resolve deficiencies identified by the FDA and believes a final regulatory decision can be achieved in 2025. The appeal process involves engaging with FDA senior leadership and external experts, reflecting CytoSorbents’ confidence in addressing the FDA’s concerns. Meanwhile, the DrugSorb-ATR application with Health Canada is under advanced review, with a decision expected in 2025 despite delays.
The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
CytoSorbents Corporation held its 2025 Annual Meeting of Stockholders on June 12, 2025, where stockholders voted on several key matters. The election of five directors was confirmed, the compensation of named executive officers was approved on a non-binding basis, and the appointment of WithumSmith+Brown, PC, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s ongoing governance and operational strategies, impacting its leadership structure and financial oversight.
The most recent analyst rating on (CTSO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
On June 11, 2025, CytoSorbents Corporation announced that the 5-day volume weighted average price per share of its common stock was below the required minimum of $2.00, leading to the expiration of the Series B Right Warrants issued in a prior Rights Offering. Consequently, payments made for the exercise of these warrants will be refunded without interest or penalty.
The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
On April 17, 2025, CytoSorbents Corporation announced the appointment of Melanie Grossman as Vice President and Corporate Controller, effective April 14, 2025. Grossman, who brings over 25 years of finance and accounting experience, will receive stock awards as an inducement grant under Nasdaq Rule 5635(c)(4). Her expertise is expected to support CytoSorbents’ growth and the potential launch of DrugSorb™-ATR in North America, enhancing the company’s operational efficiency and market positioning.
On April 14, 2025, CytoSorbents Corporation announced the appointment of Thomas Shannon as Vice President of Marketing for North America. Shannon, with over 25 years of experience in commercializing cardiovascular and critical care technologies, will lead the marketing strategy for DrugSorb™-ATR in the U.S. and Canada. This appointment comes as the company prepares for the potential launch of DrugSorb-ATR, a device aimed at reducing perioperative bleeding in patients undergoing coronary artery bypass graft surgery while on blood thinners. The device is currently under review by the U.S. FDA and Health Canada, with regulatory decisions expected in 2025.